April 3, 2024
BioTissue’s Prokera® at the Forefront of Latest Discoveries in Cryopreserved Amniotic Membrane Innovations at ASCRS 2024
MIAMI, April 2, 2024—Renowned ophthalmologists at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston are set to share groundbreaking research that offers revolutionary insights into the application of Cryopreserved Amniotic Membrane (CAM). Among these advancements is the utilization of BioTissue’s Prokera® Slim in optimizing the ocular surface across many differing clinical scenarios. A pioneer in cryopreserved human birth tissue products, BioTissue continues to lead the way in regenerative healing for chronic wounds, musculoskeletal conditions, and ocular surface diseases and disorders.
“These four studies may reshape the landscape of ocular surface space,” said BioTissue CEO Ted Davis. “The advancements highlighted in these studies not only reinforce our dedication to innovative solutions, but also emphasize the positive impact of CAM on patients’ lives.”
The following papers and posters will be featured at ASCRS:
- Effect of Cryopreserved Amniotic Membrane on Optimizing the Ocular Surface Prior to Cataract Surgery
Jeff Wongs, MD
The study evaluates the effectiveness of CAM, in particular Prokera Slim, in improving the ocular surface and enhancing the accuracy of biometry readings before cataract surgery for better post-operative refractive outcomes. Preliminary findings from 32 eyes demonstrated significant improvements in SPEED scores, NEI staining scores, and BCVA after AM treatment. Moreover, 97% of eyes achieved 20/20 BCVA one-month post-cataract surgery, with 78% attaining emmetropia, suggesting that CAM placement optimizes the ocular surface and contributes to post-surgical refractive success.
Brett P. Bielory, MD
This analysis reports the outcomes of managing a severe limbal scleral defect post-pterygium surgery using self-retained CAM, specifically Prokera. In a 57-year-old male with recurrent pterygium, self-retained AM application resulted in increased scleral thickness, complete conjunctival epithelialization, and improved visual acuity without signs of inflammation, demonstrating the effectiveness of in-office AM management for ocular surface recovery in such cases.
Ravi Krishnan, MD
This study evaluates the retrobulbar injection of micronized AM for managing intractable ocular pain. Four patients with recalcitrant ocular pain, contemplating enucleation of evisceration, showed a significant reduction in pain scores after the injection, with sustained relief and improved visual acuity observed during an average follow-up of 46-weeks, suggesting the potential utility of this approach in providing symptomatic improvement without complications.
Kurt Hanebrink, MD, Ankur A. Parikh, MD, and Amar P. Shah, MD, MBA
This study assesses intraocular lens (IOL) selection and post-cataract surgery visual outcomes in patients with epithelial basement membrane dystrophy and/or Salzmann nodular degeneration undergoing staged phototherapeutic keratectomy (PTK)/cryopreserved amniotic membrane (CAM) + cataract surgery (CE/IOL) compared to staged PTK + CE/IOL.
Paper presentations will take place at Boston Convention and Exhibition Center. Dr. Parikh is scheduled to present his paper on Saturday, April 6 at 2:20 p.m. at meeting level 2, room 260, and Dr. Wongs will present his paper on Sunday, April 7 at 4:35 p.m. at meeting level 2, room 259B. Posters will be available for viewing on-demand in the Education Hub at the convention center during the meeting and available for viewing on the ASCRS website post-meeting.
# # #
About BioTissue Holdings Inc.
BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues Biologics License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 800,000 human implants with its products and published over 390 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at biotissue.com.
Media Contact
Laura DiCaprio
McDougall Communications for BioTissue
[email protected] or (585) 434-2153
